Prof. Dr. med. Arndt Hartmann

Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie

BRAF mutation testing in melanoma: results from a German observational multicenter study (2019) Hartmann A, Schirmacher P, Sterlacci W, Koch W, Liesenfeld DB, Schif B, Garbe C Journal article Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options (2019) Ahrens M, Scheich S, Hartmann A, Bergmann L Journal article, Review article Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis (2019) Fasching P, Hartkopf AD, Gaß P, Häberle L, Akpolat-Basci L, Hein A, Volz B, et al. Journal article High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma (2019) Polifka I, Agaimy A, Herrmann E, Spath V, Trojan L, Stoeckle M, Becker F, et al. Journal article Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands (2019) Haller F, Bieg M, Will R, Koerner C, Weichenhan D, Bott A, Ishaque N, et al. Journal article MSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies (2018) Galon J, Mlecnik B, Hermitte F, Marliot F, Bifulco C, Lugli A, Nagtegaal ID, et al. Conference contribution Immunoscore feasibility study in routine postsurgical pathologic review for early-stage colon cancer (CC) cases risk-assessment (2018) Belaloui K, Malifarge E, Bohm J, Bossard C, Dienstmann R, Garcia S, Geppert CI, et al. Conference contribution A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients (2018) Häberle L, Erber R, Gaß P, Hein A, Jud S, Langemann H, Rauh C, et al. Conference contribution Transcriptomic and metabolomic profiles in renal cell carcinoma (RCC) tumors reflect ontogeny of RCC subtypes (2018) Fisel P, Buettner F, Reustle A, Klumpp V, Winter S, Rausch S, Hennenlotter J, et al. Conference contribution Loss of EZH2 at tumor invasive front is correlated with higher aggressiveness (2018) Böhm J, Muenzner JK, Caliskan A, Ndreshkjana B, Erlenbach-Wunsch K, Merkel S, Croner RS, et al. Conference contribution